Aileron Therapeutics Inc (NASDAQ:ALRN)
| 3.17 Delayed Data As of Jan 23 |  0.00 / 0.00%Today’s Change | 1.79 Today|||52-Week Range 15.00 | +33.76% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $15.4M |
Company Description
Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company engaged in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Watertown, MA.
Contact Information
Aileron Therapeutics, Inc. 285 Summer Street Boston Massachusetts 02210 |
Employees
Shareholders
| Other institutional | 8.06% |
| Mutual fund holders | 4.35% |
| Individual stakeholders | -- |
Top Executives
| Manuel C. Alves Aivado | President, Chief Executive Officer & Director |
| Susan L. Drexler | Chief Financial Officer |
| Andres Brainsky | Vice President-Clinical Development |
| David Allen Annis | Senior Vice President-Research |
